Industry Presentations

Importance of Lowering LDL-C inPatients With Recent MI


Presentations


Speakers

  • Allen J. Taylor, MD

    Allen J. Taylor, MD

    Allen J. Taylor, MD

    Allen J. Taylor, MD, is Chairman of Cardiology at MedStar Heart and Vascular Institute, including Medstar Georgetown University Hospital and MedStar Washington Hospital Center in Washington, DC. Dr. Taylor is a board-certified cardiologist and clinical researcher, specializing in cardiovascular imaging and prevention. He is a member of the corporate Board of Directors for MedStar Health, the leading academic health system in the Washington DC, Maryland region.

    Dr. Taylor obtained his medical training at Johns Hopkins University in Baltimore, MD, followed by internal medicine residency training at Walter Reed Army Medical Center, Washington DC, and a cardiovascular disease fellowship at the University of Virginia, Charlottesville, VA. During a 20-year career in the United States Army at Walter Reed, he served as the Director of Cardiovascular Research, Director of the Cardiovascular Disease Training Program, and Chief of the Cardiology service. He retired from military service in 2008 at the rank of Colonel, during which he held the Army's "A" proficiency designator and was decorated with the Legion of Merit. He is a full Professor of Medicine at the Uniformed University of the Health Sciences, Bethesda MD, and Georgetown University, Washington, DC.

    Dr. Taylor's major research accomplishments include defining the role of lipid lowering therapy on carotid atherosclerosis, focusing on HDL cholesterol and the use of niacin. His pioneering work in the field of cardiac CT includes conducting long-term prospective outcomes trials, randomized clinical trials on the utility of the technique, and methods to enhance the safety and appropriateness of cardiovascular imaging. He has published more than 210 manuscripts in the areas of imaging, lipids, prevention, cardiovascular outcomes, and quality in journals, such as Circulation, the Journal of the American Medical Association, and the New England Journal of Medicine. He receives ongoing research funding from various federal and private sources, including the NIH. He is the author and/or editor of 5 books on topics within cardiovascular disease.

    Dr. Taylor served as founding Editor-in-Chief of the Journal of Cardiovascular CT, and as Editor of the Braunwald's Heart Disease companion text atlas on cardiac CT. He is a Past President of the Society of Atherosclerosis Imaging and Prevention, and within the American College of Cardiology has held the posts of Chair of the Imaging Council, Chair of the FOCUS campaign for Appropriate Use of Cardiovascular Imaging, and member of the Board of Governors. He is a founder of the Society of Cardiovascular CT, serving on its Board of Directors from 2006-2012, and also a founder of the Certification Board of Cardiovascular CT. He serves on the board of directors for Inteleos, an organization leading certification pathways and excellence among cardiovascular imaging experts. His work on national writing groups and task forces includes multi-society guidelines on cardiac CT training, terminology, and performance, quality standards for imaging performance and radiation protection, Appropriate Use Criteria for diagnostic testing, and national standards on cardiovascular disease management and prevention.

    Dr. Taylor contributes frequently to media reports as an authority on cardiovascular disease in major regional and national venues such as the Wall Street Journal, USA Today, The New York Times, US News and World Report, CNN, Associated Press, Reuters, Forbes, National Public Radio and as a frequent commentator on national video media including Good Morning America, and the NBC and CBS Nightly News programs.
  • Robert J. Chilton, DO, FACC, FAHA

    Robert J. Chilton, DO, FACC, FAHA

    Robert J. Chilton, DO, FACC, FAHA

    Robert J. Chilton, DO, is an Associate Professor of Medicine and Director of the Cardiac Catheterization Laboratory at the Audie Murphy VA/ UT Health San Antonio.

    A fellow of the American College of Cardiology, American College of Physicians, American College of Osteopathic Internists, and American Heart Association, Dr. Chilton also chairs the Electrophysiology Board Examination for the American Osteopathic Association and presides over the San Antonio chapters of both the Cardiovascular Society and American Heart Association.

    Dr. Chilton received his Bachelor of Science degree from Philips University, Enid, Oklahoma, and his DO from the University of Osteopathic Medicine and Surgery, Des Moines, Iowa. He completed his internship at Wright-Patterson Air Force Base, Dayton, Ohio; his residency at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and a cardiology fellowship at the Wilford Hall United States Air Force Medical Center, San Antonio, Texas. Dr. Chilton is board certified in internal medicine, cardiovascular disease, and electrophysiology.

    Over the past 20 years, Dr. Chilton has authored numerous articles, book chapters, abstracts, and presentations on cardiology. He has developed educational materials and has lectured widely, garnering several awards for his academic contributions, including 1994 Outstanding Teacher from the UT San Antonio.
  • Sripal Bangalore, MD, MHA

    Sripal Bangalore, MD, MHA

    Sripal Bangalore, MD, MHA

    Dr. Bangalore is an interventional cardiologist and a Professor of Medicine at New York University School of Medicine. He is the Director of Complex Coronary Intervention; Director of Research for the cardiac catheterization laboratory and the Director for the Cardiovascular Outcomes Group. His clinical expertise is in complex coronary intervention including CTOs, ultra low volume/zero contrast PCI, and renal denervation. His research interests are in comparative effectiveness studies for cardiovascular diseases, particularly stable ischemic heart disease, acute coronary syndromes, hypertension and dyslipidemia. Dr. Bangalore has received grants from the National Institutes of Health, Agency for Healthcare Research and Quality, American Heart Association and from the industry. He has published over 350 articles in leading national and international journals including the NEJM, JAMA, Lancet, Circulation and JACC. He is the principal investigator of the ISCHEMIA CKD trial, which is a randomized trial in patients with advanced chronic kidney disease and abnormal stress test, carried out in 33 countries and up to 350 clinical sites. The trial is testing the effectiveness of an initial invasive strategy of cath and revascularization with optimal medical therapy versus a conservative strategy of optimal medical therapy alone in patients with chronic kidney disease. His other areas of interest include comparative effectiveness of coronary artery bypass surgery (CABG) vs. percutaneous coronary intervention (PCI), evaluating the efficacy and safety of various stent types in patients undergoing PCI, including patients with diabetes and those in patients with ST segment elevation myocardial infarction and comparative effectiveness of drug eluting stents vs. bare metal stents. He has won a number of awards including the Dr. Gregory Braden Memorial Interventional Cardiology Fellow of the Year Award from the Society for Cardiovascular Angiography and Intervention and the Douglas P. Zipes Distinguished Young Scientist award from the American College of Cardiology.
  • Daniel Soffer, MD, FNLA

    Daniel Soffer, MD, FNLA

    Daniel Soffer, MD, FNLA

    Dr. Soffer is a full-time clinician and Clinical Associate Professor of Medicine in the Division of General Internal Medicine and Division of Translational Medicine and Human Genetics at Perelman School of Medicine of the University of Pennsylvania. He is a lipid specialist whose clinical focus is Preventive Cardiovascular Medicine and General Internal Medicine. He is a Diplomate of the American Board of Internal Medicine and American Board of Clinical Lipidology. Dr. Soffer is involved in multiple education activities at the University of Pennsylvania, the National Lipid Association (NLA), and commercial continuing medical education as well. He is involved with many NLA activities including administration, education, meeting planning, and publishing. He is Immediate Past President (2018/2019) of the Northeast Chapter of the NLA and he is also the co-director of the Philadelphia Lipid and Atherosclerosis Club (PLAC). He is the co-Editor of LipidSpin and co-Director of the Foundations of Lipidology course for the NLA. In addition to clinical medicine and teaching, he also participates as an investigator in ongoing clinical research with lipid-modifying pharmacotherapies. He earned a BA from the University of Pennsylvania and also graduated from the University of Pennsylvania Medical School. His internship and residency were completed at the Hospital of the University of Pennsylvania.
  • Carl (Chip) Lavie, JR., MD, FACC, FACP, FCCP

    Carl (Chip) Lavie, JR., MD, FACC, FACP, FCCP

    Carl (Chip) Lavie, JR., MD, FACC, FACP, FCCP

    Dr. Lavie graduated from Louisiana State University Medical School in 1983 and completed internal medicine residency at Ochsner and fellowship in cardiovascular diseases at Mayo, where he joined the faculty in 1989. Dr. Lavie is Professor of Medicine and Medical Director, Cardiac Rehabilitation and Preventive Cardiology; Director, Exercise Testing Laboratory; and Staff Cardiologist, Echocardiographic Laboratory at the John Ochsner Heart and Vascular Institute in New Orleans, Ochsner Clinical School-The University of Queensland School of Medicine and he previously served for 10 years as Associate Director of the Internal Medicine Training program. He served as a Consultant in the Department of Preventive Medicine at the Pennington Biomedical Research Center in Baton Rouge, Louisiana from January 2012-October 2014. Dr. Lavie’s research interests include cardiac rehabilitation and prevention, lipids, hypertension, obesity, and exercise, as well as noninvasive testing, encompassing echocardiography, exercise testing, and nuclear cardiology. He is the author of over 1000 medical publications including two cardiology textbooks, and nearly 60 book chapters, and nearly 750 listed currently on Pub Med with h-index of 101. Dr. Lavie serves as a frequent lecturer, reviewer for several medical journals, and is Associate Editor and Cardiovascular Section Editor of the Mayo Clinic Proceedings and is Editor in Chief of Progress in Cardiovascular Diseases and Associate Editor of Current Problems in Cardiology and Progress in Preventive Medicine and serves on the Editorial Boards of the Journal of the American College of Cardiology, American Journal of Cardiology, Heart, Canadian Journal of Cardiology, Sports Medicine, Journal of Cardiopulmonary Rehabilitation Prevention, and 35 other Journals. For 2011 till now, he has served as Chairman of the Document Oversights Committee for AACVPR. For the years 2003 and 2004 he served as Chairman of Vascular, Hypertension and Prevention for the American College of Cardiology and he has been an elite reviewer for JACC for 7 years, also receiving the Simon Dack Award as a life-time, Hall of Fame,reviewer. In 2013, he gave Key-Note lectures for both the American College of Sports Medicine and the Cardiac Rehabilitation one for the AACVPR, where he received the 2013 Research Award.In 2019, he won the first John Ochsner Award and was named Ochsner Alumnus of the Year. From a personal stand-point, he is an avid sports fan and competitive runner, with personal records in the 5K, 10K, Half-Marathon and Marathon of 18:30,38:30,1:24:30,and 3:10, respectively. He is the author of “The Obesity Paradox” released April, 2014.
  • Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

    Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

    Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

    Dr. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in Medicine and Cardiology. He subsequently pursued training in Interventional Cardiology at the Complutense University of Madrid in Spain. Ultimately, Dr. Angiolillo received his PhD in Cellular and Molecular Cardiology. After completing his training in the most prestigious academic centers in Europe, Dr. Angiolillo joined the University of Florida College of Medicine-Jacksonville in 2004. Currently, Dr. Angiolillo is a Professor of Medicine with Tenure status. He is also the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Dr. Angiolillo is triple board certified by the American Board of Internal Medicine (Internal Medicine, Cardiovascular Disease, Interventional Cardiology).

    Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions. Amongst these he has received the 2013 Outstanding Achievement Award from the European Society of Cardiology and since 2014 he has been in the top 1 percent of most-cited researchers worldwide according to Clarivate Analytics (formerly Thomson Reuters’ list of The World’s Most Influential Scientific Minds). He has also been a key investigator in the clinical development of numerous novel antithrombotic agents, working along slide with drug regulating agencies in the United States (FDA) and Europe (EMA), towards approval of these drugs and product labeling updates. His success in obtaining extramural funding has allowed to develop one of the most active clinical research centers in the United States as well as one of the leading centers for thrombosis research in the world.

    Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as textbooks of cardiovascular medicine. He has authored over 400 peer-reviewed articles with over 31,000 citations and an H-index of 89. He has authored nearly 40 book chapters, and he is the editor of his own textbook on antithrombotic medicine. Due to his major contributions to the field of antithrombotic therapy in patients with cardiovascular disease manifestations, Dr. Angiolillo has been invited to deliver numerous lectures across the globe. His international visibility has also allowed him to develop a very active research program attracting physicians and scientists from across the globe to train under his leadership. In addition, to these responsibilities, Dr. Angiolillo has been a clinical mentor to numerous residents and fellows for which he has been recognized in multiple occasions with an Exemplary Teacher Award. His leadership role as an academic clinician scientist has allowed to him to nurture and promote career growth and development of many young trainees pursuing both academic and clinical careers in the United States and abroad.

    Dr. Angiolillo is an active member of many cardiovascular societies in the Unites States and Europe. In addition, he is on the editorial board of numerous cardiovascular journals, some of which he also holds leadership roles. He is a scientific reviewer for many major journals and extramural funding agencies, including the National Institute of Health, and other federal funding agencies in several European countries. He is also Chair of the American Board of Internal Medicine examination writing committee in Interventional Cardiology.
  • Karol Watson, MD, PhD

    Karol Watson, MD, PhD

    Karol Watson, MD, PhD

    Dr. Karol Watson is an attending cardiologist and a Professor of Medicine/Cardiology at the David Geffen School of Medicine at UCLA. She is Director of the UCLA Women’s Cardiovascular Health Center, the UCLA-Barbra Streisand Women’s Heart Health Program, Co-Director of the UCLA Program in Preventive Cardiology, and Director of the UCLA Fellowship Program in Cardiovascular Diseases. Dr. Watson is a principal investigator for several large National Institutes of Health research studies including the Diabetes Prevention Program Outcomes Study and the Multi-ethnic Study of Atherosclerosis. She is a Fellow of the American College of Cardiology and a member of the American Heart Association. She is also a Board member of the American Heart Association, Western States Affiliate, and Chairperson of the Scientific Advisory Board for Womenheart, the largest national organization for women survivors of heart disease.
  • Steve Raskin, MD, FACC

    Steve Raskin, MD, FACC

    Steve Raskin, MD, FACC

    Steve Raskin has practiced clinical cardiology for more than 40 years and has served as a mentor at the UC Berkeley, UCSF Combined Medical School Program and Clinical Professor of Medicine at UCSF. He currently is the Director of the Sutter Eastbay Medical Foundation Lipid Clinic. He obtained his medical degree from the Medical College of Wisconsin followed by internship and medical residency at the Boston City Hospital. Cardiology fellowship was completed at Mt. Zion-University of California, San Francisco. Dr. Raskin is a member of AOA and is board certified in cardiology, cardiovascular computed tomography and clinical lipidology. He is an avid photographer and ocean sailor completing two transpacific crossings.